Annals of Oncology 7:99-102, 1996
© 1996 European Society for Medical Oncology
other |
Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study
1Medical Oncology Division, University Hospital Parma, Italy
2Chair of Chemotherapy, University of Milan Italy
3Ciba-Geigy Basel, Switzerland
Correspondence to: Giorgio Cocconi, M.D. Medical Oncology Division University Hospital 43100 Parma Italy
PURPOSE: To evaluate the endocrine effects as well as the pharmacokinetic parameters, efficacy and safety of letrozole, a new fourth-generation non-steroidal aromatase in hibitor.
Patients and methods: Fourteen postrnenopausal women with progressive metastatic breast cancer, previously treated with endocrine therapy and/or chemotherapy for advanced disease, were treated with 0.5 mg daily doses of letrozole, orally. Endocrine and pharmacokinetic measurements were made before treatment and on days 14, 28, 56, and 84 of therapy.
RESULTS: Letrozole induced a >86% decrease in plasma estrone and a =67% reduction in circulating estradiol from day 14 on. There was a statistically significant decrease in plasma cortisol, which appeared clinically irrelevant since all values remained within the normal range. No significant changes in aldosterone concentration were noted. One patient achieved a complete response (CR) and 4 patients a partial response (PR), with an objective response rate of 36% (95% CI 13% to 6 5%). Median duration of response was 24 months, ranging from 4 to 44 months. No toxic effects attributable to letrozole were noted in any patient.
CONCLUSION: Letrozole appears to be a very promising new antiaromatase drug. The characteristics of the patients more likely to respond, taking into account prior systemic treatment, should be defined by future studies. Further phase II and phase III studies comparing letrozole to other available second or even first-line endocrine-therapy agents, are war ranted.
aromatase inhibitors, breast carconoma, endocrine therapy, letrozole
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Rossi, A. Morabito, E. De Maio, F. Di Rella, G. Esposito, A. Gravina, V. Labonia, G. Landi, F. Nuzzo, C. Pacilio, et al. Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer J. Clin. Oncol., January 10, 2008; 26(2): 264 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. U. Buzdar and J. Cuzick Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data Clin. Cancer Res., February 1, 2006; 12(3): 1037s - 1048s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Tobias Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention Ann. Onc., December 1, 2004; 15(12): 1738 - 1747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. E. Smith and M. Dowsett Aromatase Inhibitors in Breast Cancer N. Engl. J. Med., June 12, 2003; 348(24): 2431 - 2442. [Full Text] [PDF]
|
|
|
|
|
|
A. U. Buzdar Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Clin. Cancer Res., January 1, 2003; 9(1): 468S - 472S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ligibel and E. P. Winer Clinical Differences among the Aromatase Inhibitors Clin. Cancer Res., January 1, 2003; 9(1): 473S - 479S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Cohen, J. R. Johnson, N. Li, G. Chen, and R. Pazdur Approval Summary: Letrozole in the Treatment of Postmenopausal Women with Advanced Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 665 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Buzdar and A. Howell Advances in Aromatase Inhibition: Clinical Efficacy and Tolerability in the Treatment of Breast Cancer Clin. Cancer Res., September 1, 2001; 7(9): 2620 - 2635. [Full Text] [PDF]
|
|